m+Medelevator.RU
← Поиск публикаций
Discover nano · 2025

Design of a dual-responsive system based on ferrocene and porous Fe2O3 microspheres for therapeutic applications.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Seo Dongseong, Kim Tae Ha, Kim Sangwoo, Kim Sang-Hyun, Park Gi Dae, Sung Daekyung

Аннотация

This paper reports the development of an advanced dual-stimuli-responsive drug-delivery system designed to enhance the precision and efficiency of targeted therapies. The system integrates the unique properties of ferrocene and porous iron oxide microspheres (P-Fe2O3) to respond to reactive oxygen species and external magnetic fields. Ferrocene, with its well-known redox properties, facilitates selective drug release in oxidative environments commonly found in tumor tissues, while P-Fe2O3 imparts magnetism and porosity for improved targeting and controlled release under magnetic stimuli. P-Fe2O3 is synthesized using an environmentally friendly, continuous, and scalable spray pyrolysis technique, whereas ferrocene-based polymers are prepared via radical polymerization. As conventional nanostructured microsphere syntheses are time intensive, use toxic acids, and face scale-up challenges, this study proposes spray pyrolysis as an efficient approach for producing well-designed porous iron oxide microspheres capable of loading ferrocene nanoparticles on a large scale. Combining these materials yields a synergistic effect, optimizing drug delivery through selective release and enhanced control mechanisms. The drug release profiles of the model compounds are assessed, underscoring the potential of this dual-response system for precise, efficient, and safe therapeutic delivery. This innovative platform demonstrates significant potential as a next-generation drug-delivery technology aimed at minimizing side effects and maximizing therapeutic outcomes in oncological applications.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты